Clinical trials: Biochemically Recurrent
Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with…
- Conditions
- Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
- Trial name
- DIVINE (NCT06378866)
- Testing
- Abiraterone, Apalutamide, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 532 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma, PSA Failure
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not…
- Conditions
- Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT04519879
- Testing
- Clinical Observation, Patient Observation, Questionnaire Administration
- Where
- 7 sites in United States
- Volunteers
- 133 people
- Sponsor
- City of Hope Medical Center
Metastatic Castration Sensitive Prostate Cancer
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
The purpose of this study is to find out what effects, good and/or bad, taking ipilimumab with degarelix before surgery to remove the prostate, followed by more degarelix and ipilimumab after the surgery, will have on prostate…
- Trial name
- NCT02020070
- Testing
- Degarelix, Ipilimumab, Radical Prostatectomy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Prostate Cancer, Prostate Cancer
IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy
Background: Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year.
- Trial name
- NCT07686380
- Testing
- N-803, ETBX-71 Vaccine, 18F-DCFPyL
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Biochemical Recurrent Prostate Cancer
Radium-223 in Biochemically Recurrent Prostate Cancer
Background: Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer.
- Trial name
- NCT04206319
- Testing
- Radium-223, 18F Sodium Fluoride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with relapsed prostate cancer.
- Trial name
- NCT01272050
- Testing
- radiation therapy
- Where
- 28 sites in Belgium, Germany and 1 more
- Volunteers
- 350 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer
18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer
Single centre prospective cohort phase II study of 18F-PSMA-1007 PET/CT imaging in patients with biochemically recurrent or high-risk prostate cancer.
- Trial name
- NCT04733768
- Testing
- 18F-PSMA-1007
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Alberta
Prostate Cancer Recurrent
PSMA-RLT in Biochemically Recurrent PCa
Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA > nadir + 2ng/ml after radiotherapy (RT)…
- Trial name
- NCT06220188
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
This phase II trial studies how well durvalumab and olaparib work in treating prostate cancer in men predicted to have specific genetic mutations (a high neoantigen load).
- Trial name
- NCT04336943
- Testing
- Durvalumab, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1]) after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided…
- Trial name
- NCT06105918
- Testing
- Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer.
- Trial name
- NCT00080899
- Testing
- fenretinide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
This phase II trial evaluates the impact of cancer therapy in the patients' home compared to in the clinic on safety, side effects, patient preference, and satisfaction in Black men with prostate cancer that has spread to nearby…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07073794
- Testing
- Cancer Therapeutic Procedure, Health Care Delivery, Questionnaire Administration
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Biochemically Recurrent
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
Background: Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans…
- Trial name
- NCT05588128
- Testing
- 18F-DCFpyL
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scan on treatment strategies for patients with prostate cancer.
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma
- Trial name
- NCT04050215
- Testing
- Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
- Where
- United States
- Volunteers
- 937 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Perifosine in Treating Patients With Recurrent Prostate Cancer
Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent prostate cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00058214
- Testing
- perifosine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01787331
- Testing
- Itraconazole, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, High-risk Biochemical Recurrence
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
- Conditions
- Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT06555796
- Testing
- Xaluritamig
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Prostate Cancer
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
RATIONALE: White button mushroom extract may stop or delay the development of recurrent prostate cancer. PURPOSE: This phase I trial is studying the side effects and best dose of white button mushroom extract in treating patients…
- Trial name
- NCT00779168
- Testing
- white button mushroom extract, flow cytometry, immunologic technique
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences